Abstract:

BACKGROUND: It is of significance for looking for ideal pharmaceutical dosage form and administration route to make sure direct action in local region, improve selection of high-concentration drug to local target tissue, prolong drug action, and prevent local recurrence of breast cancer.
OBJECTIVE: To explore the clinical safety of fluorouracil implants for modified radical mastectomy, and investigate the new way to prevent the local recurrence of breast cancer.
METHODS: A total of 63 cases with breast cancer treated by modified radical mastectomy in TNM stage of Ⅰ+Ⅱ (n=35) and Ⅲ(n=28) were randomly divided into control group (n=31) and implant group (n=32). Fluorouracil implants (600 mg in total, less than 100 mg at each site) were multiple-implanted below the tumor and in the armpits, subclavian vascular region, and axillary vascular area, so as to observe the incision infection or dehiscence, the subcutaneous fluid volume after 8 days, flap necrosis, limb edema, stitches days, WBC, RBC, hepatic and renal function.
RESULTS AND CONCLUSION: The differences in the incision infection or dehiscence, the subcutaneous fluid volume after 5 days, flap necrosis, limb edema, stitches days, and RBC between two groups were not significantly. Levels of WBC, glutamic-pyruvic transaminase, and creatinine were significantly increased after operation compared with before operation (P < 0.05), but there was no significant difference between the two groups (P > 0.05), suggesting that the method of implanting sustained-release fluorouracil for modified radical mastectomy was safe, and it might become an effective way to  local chemotherapy for breast cancer postoperatively.